Clinical Trials Logo

Spinocerebellar Ataxias clinical trials

View clinical trials related to Spinocerebellar Ataxias.

Filter by:

NCT ID: NCT04055532 Withdrawn - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Biomarkers in Neurodegenerative Diseases

Start date: October 1, 2019
Phase:
Study type: Observational [Patient Registry]

The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.

NCT ID: NCT03885167 Completed - Clinical trials for Spinocerebellar Ataxia Type 3

Identification of Biomarkers in Spinocerebellar Ataxia 3

SCA3
Start date: February 21, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to examine the differences in cerebral spinal fluid (CSF) and blood of patients with spinocerebellar ataxias and healthy volunteers. The goal of this project is to identify new biomarkers that are useful for characterizing spinocerebellar ataxias and identify targets for treatment or prevention of this condition.

NCT ID: NCT03770377 Withdrawn - Stroke Clinical Trials

Laryngeal Adaptation for Speech and Swallowing

Start date: August 24, 2018
Phase: N/A
Study type: Interventional

This study will test laryngeal adaptation in speech and swallowing function in healthy adults, in patients with cerebral stroke, and in patients with spinocerebellar ataxia type 6. The findings from this proposal will be the first step toward implementing rehabilitation techniques that help patients to prevent speech and swallowing errors before they occur.

NCT ID: NCT03745248 Completed - Ataxia Clinical Trials

Aerobic Exercise, Balance Training, and Ataxia

Start date: November 14, 2018
Phase: N/A
Study type: Interventional

The first aim is to show aerobic training improves degenerative cerebellar patients functionally The second aim is to compare the effects of balance and aerobic training on degenerative cerebellar disease.

NCT ID: NCT03701776 Completed - Ataxia Clinical Trials

Ataxia and Exercise Disease Using MRI and Gait Analysis

Start date: January 13, 2020
Phase: N/A
Study type: Interventional

The first aim is to show balance training improves DCD individual's ability to compensate for their activity limitations, but does not impact disease progression. The second aim is to demonstrate aerobic exercise improves balance and gait in DCD persons by affecting brain processes and slowing cerebellar atrophy.

NCT ID: NCT03701399 Active, not recruiting - Clinical trials for Spinocerebellar Ataxias

Troriluzole in Adult Subjects With Spinocerebellar Ataxia

Start date: March 8, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).

NCT ID: NCT03687190 Completed - Clinical trials for Spinocerebellar Ataxias

Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients

Start date: May 13, 2013
Phase: N/A
Study type: Interventional

Spinocerebellar atrophy is the most common autosomal dominant inherited ataxia. There are over thirty subtypes, which characterize neurologic features differently. They all have obvious substantial cerebellar atrophies in image, and unstable gait、ataxia. In general a prevalence of about three cases per 100 000 people is assumed, but this may be an underestimate. Progressive neurologic degeneration, in about 10-20 years, will leads to disability or wheelchair-dependent. Accompanying with fatigue, downhill course of the disease often made patients depressive and hopeless. The recent review of researches concludes no effective therapy for the disease. The purpose of the investigator's study is to explore the Tai-chi exercise effect for spinocerebellar ataxia.

NCT ID: NCT03660917 Not yet recruiting - SCA7 Clinical Trials

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Start date: January 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.

NCT ID: NCT03487367 Active, not recruiting - Clinical trials for Spinocerebellar Ataxia Type 1

Clinical Trial Readiness for SCA1 and SCA3

READISCA
Start date: August 16, 2018
Phase:
Study type: Observational

The investigators plan to fill the gap between the current state of clinical trial readiness and the optimal one for SCA1 and SCA3, which are fatal rare diseases with no treatments. Through US-European collaborations, the investigators will establish the world's largest cohorts of subjects at the earliest disease stages, who will benefit most from treatments, validate an ability to detect disease onset and early progression by imaging markers, even prior to ataxia onset, and identify clinical trial designs that will generate the most conclusive results on treatment efficacy with small populations of patients.

NCT ID: NCT03408080 Active, not recruiting - Clinical trials for Spinocerebellar Ataxias

Open Pilot Trial of BHV-4157

Start date: December 15, 2017
Phase: Phase 3
Study type: Interventional

24 adults, between the ages of 18 and 75 years, with cerebellar ataxia will be enrolled in a 12 week trial of BHV-4157 for treatment of ataxia. BHV-4157 is a pro-drug of riluzole (which is currently FDA-approved for ALS, Lou Gehrig's disease). There will be 5 visits to UCLA required--Screening when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; Baseline when general and neurological examination and questionnaires will be administered and study drug dispensed; Week 4 and Week 12 when general and neurological examination, blood and urine testing, ECG, and questionnaires will be administered; 2 weeks after finishing study drug when general examination and blood testing will be completed. There is an option for a 36 week extension of the study drug trial.